We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clears Updated Label for Novartis’ Beovu
The FDA has approved a new label for Novartis’ wet age-related macular degeneration (AMD) treatment Beovu (brolucizumab) with added safety information.